-
1 Comment
Bionano Genomics, Inc is currently in a long term uptrend where the price is trading 18.5% above its 200 day moving average.
From a valuation standpoint, the stock is 92.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 96.0.
Bionano Genomics, Inc's total revenue rose by 43.1% to $4M since the same quarter in the previous year.
Its net income has dropped by 48.5% to $-12M since the same quarter in the previous year.
Finally, its free cash flow fell by 27.3% to $-12M since the same quarter in the previous year.
Based on the above factors, Bionano Genomics, Inc gets an overall score of 3/5.
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
ISIN | US09075F3055 |
Industry | Medical Instruments & Supplies |
Sector | Healthcare |
Market Cap | 12M |
---|---|
PE Ratio | None |
Target Price | 7.3333 |
Beta | 2.37 |
Dividend Yield | None |
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. The company offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. It also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic data from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, the company offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BNGO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025